ライフサイエンスコーパス: valvular disease

1 g former drinkers and those with significant valvular disease.

2 c dysfunction is the result of aortic and/or valvular disease.

3 on as a potential genetic basis for calcific valvular disease.

4 explain the association of aortic vessel and valvular disease.

5 nd NOTCH mutations are associated with adult valvular disease.

6 the engineering of effective treatments for valvular disease.

7 accepted as the gold standard for therapy of valvular disease.

8 ss has been made in the evaluation of mitral valvular disease.

9 n patients with both congenital and acquired valvular disease.

10 ay include carotid artery disease or cardiac valvular disease.

11 e insights into the molecular basis of adult valvular disease.

12 aking antiarrhythmic drugs, or patients with valvular disease.

13 ad significant aortic regurgitation or other valvular disease.

14 No patient had coronary artery or primary valvular disease.

15 prone to developing severe aortic disease or valvular disease.

16 ring follow-up, in most cases as a result of valvular disease.

17 nt genetic component in death resulting from valvular diseases.

18 cular disease (11.7%, 10.8%, and 17.6%), and valvular disease (16.7%, 21.2%, and 35.8%), increased, a

19 scular disorders (39%), alcohol abuse (36%), valvular disease (32%), liver disease (30%), diabetes (2

20 s include catheters, AV grafts, and calcific valvular disease, all in conjunction with frequent acces

21 tions of high-energy phosphate metabolism in valvular disease and cardiomyopathy to the clinical seve

22 valve structures is the most common form of valvular disease and is characterized by the appearance

23 ibrillation is associated with more advanced valvular disease and noncardiac comorbidities.

24 cularization is a recognized feature of many valvular diseases and is established by numerous angioge

25 e of coronary artery disease, heart failure, valvular disease, and arrhythmia by 45 years of age was

26 h as coronary artery disease, heart failure, valvular disease, and arrhythmia.

27 RIC) study who were in sinus rhythm, free of valvular disease, and had acceptable quality 3-dimension

28 ic disease, hypertension, heart failure, and valvular disease, and it is a strong predictor of increa

29 on, diabetes, ventricular failure, rheumatic valvular disease, and prior stroke or other embolic even

30 lder, had a higher incidence of diabetes and valvular disease, and were more likely to be presenting

31 uch as hypertension, ischemic heart disease, valvular diseases, and endocrine disorders.

32 Moderate or severe valvular diseases are notably common in this population

33 ore likely than men to have hypertension and valvular disease as the underlying etiology.

34 cterization of the mechanism and severity of valvular disease as well as determining the hemodynamic

35 lacement was 22 percent in the patients with valvular disease, but only 8 percent in those without it

36 phy, dilation or dysfunction, or significant valvular disease), C1 (clinical HF without prior hospita

37 Aortic insufficiency is a valvular disease characterized by left ventricular volum

38 Cardiac valvular diseases contribute to >42,000 deaths yearly in

39 han 65 years on April 1, 2002, without prior valvular disease, coronary artery disease, heart failure

40 in diagnosis and treatment of heart failure, valvular disease, coronary disease, and congenital disea

41 For patients without significant valvular disease, decisions around anticoagulation thera

42 ol use, significant coronary artery disease, valvular disease, diabetes mellitus, or pretransplant hy

43 sk factors for AF (body mass index, smoking, valvular disease, diabetes, electrocardiographic left ve

44 Significant valvular disease did not correlate with the dose or dura

45 rtic stenosis (AS) is one of the most common valvular diseases encountered in clinical practice.

46 for the perioperative evaluation of cardiac valvular disease, especially during surgical procedures

47 tery disease, heart failure, and significant valvular disease from the fifth visit of the ARIC study

48 5-hydroxytryptamine (5-HT)]-mediated cardiac valvular disease has been commonly observed in patients

49 ar function, ischemia, pericardial effusion, valvular disease, heart donor status and arrhythmia.

50 es, including advanced calcific arterial and valvular disease; however, the mechanisms of accelerated

51 ological (such as exercise) or pathological (valvular disease, hypertension, or obesity) increase in

52 morbid conditions (congestive heart failure, valvular disease, hypertension, paralysis, neurologic di

53 c heart disease, cardiomyopathy, significant valvular disease, hyperthyroidism, or hypertension that

54 primary indication for surgery was isolated valvular disease in 41 patients: aortic stenosis (AS; n=

55 ic heart disease is the most common cause of valvular disease in developing countries.

56 tomatic heart disease in general, and aortic valvular disease in particular, following mediastinal ir

57 surgical management of patients with aortic valvular disease is described.

58 d pressure <140/90; and absence of diabetes, valvular disease, LV wall motion abnormality, or antihyp

59 f valvulogenesis and in the context of adult valvular disease may recapitulate their embryonic roles.

60 patients with angina pectoris without known valvular disease (n = 95).

61 Neither the presence of valvular disease nor changes in the echocardiographic fi

62 described in the initial report, significant valvular disease on initial postexposure echocardiograph

63 seases of the myocardium, and the effects of valvular disease on myocardial function, and to advance

64 Patients with significant valvular disease or documented contraindication to aspir

65 lder (OR, 1.3 [CI, 1.0 to 1.7]), significant valvular disease (OR, 2.1 [CI, 1.2 to 3.6]), history of

66 gery, hypertrophic cardiomyopathy, rheumatic valvular disease, or greater than mild mitral stenosis).

67 r than 30 years, history of heart failure or valvular disease, pacemaker implantation, and uninterpre

68 der age, diabetes mellitus, and a history of valvular disease predicted both types of HF (P</=0.0025

69 y surveillance and overutilization of TTE in valvular disease provides a model to study variation in

70 tients without a history of heart failure or valvular disease referred for exercise echocardiography

71 disease (RR, 6.1), heart failure (RR, 19.4), valvular disease (RR, 13.6), and arrhythmia (RR, 6.0; al

72 proportions of deaths from heart failure and valvular disease specifically increased with declining e

73 Vitamin D plays no etiologic role in cardiac valvular disease, such as that observed in Williams synd

74 aortic arch anomalies, left-to-right shunts, valvular disease, tetralogy of Fallot, and truncus arter

75 sers of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the ma

76 rformed a study to determine the relation of valvular disease to other clinical features of lupus, wh

77 mal or persistent AF and without significant valvular disease, uncontrolled hypertension, coronary ar

78 re AS (valve area </= 1 cm(2)) without other valvular disease underwent cardiac catheterization.

79 death resulting from aortic, mitral, and all valvular diseases using a population-based genealogy lin

80 diography and transthoracic echocardiography.Valvular disease was common and increased with time foll

81 duals without prior myocardial infarction or valvular disease, with an adjusted HR of 6.5 (CI 3.1 to

82 s the surprising effect of producing cardiac valvular disease without bone involvement.